Murphy & Mullick Capital Management’s GSK GSK Stock Holding History

Murphy & Mullick Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38K	Hold	689	–	–	0.03%	320
2025 Q4	$33.8K	Hold	689	–	–	0.02%	341
2025 Q3	$29.7K	Sell	689 -66	-9%	-$2.58K	0.02%	341
2025 Q2	$28K	Buy	755 +66	+10%	+$2.52K	0.02%	335
2025 Q1	$26.7K	Hold	689	–	–	0.03%	334
2024 Q4	$23.3K	Buy	+689	New	+$24.8K	0.02%	344

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Murphy & Mullick Capital Management's GSK Position: Q1 2026 in Review

Murphy & Mullick Capital Management held its GSK (GSK) position steady in Q1 2026 at 689 shares worth $38K. The position accounts for 0.03% of the portfolio, ranked #320.

Murphy & Mullick Capital Management first reported a position in GSK in Q4 2024 and has held it in 6 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Murphy & Mullick Capital Management held 689 shares of GSK worth $38K as of Q1 2026.
Murphy & Mullick Capital Management left its GSK share count unchanged in Q1 2026.
GSK made up 0.03% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #320 holding.
Murphy & Mullick Capital Management first reported a position in GSK in Q4 2024 and has held it in 6 quarters since.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.